SGLT2 inhibitors block SGLT2 cotransporters in the proximal tubules of thekidney, thereby inhibiting renal glucose reabsorption and causing glycosuria,leading to a reduction in blood glucose levels and a reduction in HbA1c of about0.5–1.0% in patients with diabetes, while these effects are attenuated innon-diabetic patients [64]. Here, SLC5A2 is linked to diabetes mellitus.